The company's flagship product EPIAO is the number 1 brand in the EPO market. Second lead product TPIAO has gained rapid physician acceptance for thrombocytopenia and is making a meaningful contribution to the company s top line growth. The recent deal with US-based AMAG Pharmaceuticals will boost SSRX expansion into IV Iron market and sustain long term growth.
3SBio's third-quarter resuts were solid and in line with our expectations on an adjusted basis. Net revenues amounted to RMB68.2 million (US$10.0 million) in the third quarter 2008, compared with RMB56.1 million in the third quarter 2007, representing an increase of 21.6%.
We maintain our Buy rating on 3SBio.
The Bull of the Day is one of the latest Buy recommendations from Zacks Equity Research. Our team of analysts consistently identify stocks set to outperform the market over the next six months. Discover More Bull of the Day stocks.

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index